GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Octapharma has received approval from the US FDA for a new 2-g formulation of Fibryga for use in patients with AFD.

Day One Biopharmaceuticals has concluded its acquisition of Mersana Therapeutics after meeting all the tender offer ...

Ypsomed will establish its first manufacturing facility in the US. The company has selected Holly Springs in Wake County, ...

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

Cellenkos has received orphan drug designation from the US FDA for its investigational CK0804 Treg therapy to treat ...

Zai Lab has received approval from China’s NMPA for the sNDA for Augtyro to treat adult patients with solid tumours ...

The CDC now recommends 11 vaccines for routine administration in childhood, which it says better allows for “flexibility and ...

Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...

Reporter Ross Law and editors Abigail Beaney and Robert Barrie reflect on a busy 2025, along with discusing forecasts for ...